id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
27,,,,,,,,,,,,,,,2024-05-01T18:20:49+06:00,BSH - H12203242396,,Paclitaxel- Carboplatin- Trastuzumab,2022-03-16,6.0,"Had 08 cycles of Inj. Doxorubicin+ Cyclophosphamide+ Carboplatin + Docetaxel based CT
up to 23.12.2021 (@BSMMU)> Surgey> Now 2nd line chemotherapy with Pacli-Carbo-Trastuzumab on
16/03/22 at India. Cycle 6 completed on 29.06.2022.
Maintenance therapy with Trastuzumab started on 20.07.2022 in India. M32 was due on 20.02.2024",2023-09-13,,2024-02-20,,,2023-09-13,,Breast,24,Upper middle class,BSBSC-240000024,MRS. SHAFIKA KHANDAKER RUMA,1732597522,1979-03-30,Female,,,,,Dr Md Arifur Rahman,BSH,,2nd Line,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,"C50.9- Breast, unspecified",Breast,,,,Stable,Alive,CR,CR,,,CR,,,,,,,,,,,,,,,,,
